GNLX Genelux Corporation
$2.49▲ +0.40%
Healthcare
Other
After hours
$2.60▲ +4.42%
Sep 11, 7:30 PM ET
Volume 146.9K
Avg Volume (10D) 354.8K
Key Metrics & Fundamentals
Market Cap
$112.66M
P/E Ratio
–
Div Yield
–%
52W Range
2.29 - 8.54
% vs 50 MA
-10.26%
% vs 200 MA
-17.26%
RSI-14
40.4
MACD Histogram
-0.0100
Beta (1Y vs SPY)
2.17
Free Cash Flow
-$7.98M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$9.55M
COGS
–
Operating Exp
$9.65M
Operating Income
-$9.65M
EBIT
-$9.65M
Pretax Income
-$9.47M
Net Income
-$9.47M
EPS (Diluted)
-0.21
Price & Volume History
Loading chart…
Recent News
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
GlobeNewswire · Sep 9, 2026 8:01 PM
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
GlobeNewswire · Aug 13, 2026 8:20 PM
Attovia Therapeutics Appoints John W. Smither to Board of Directors
GlobeNewswire · Jul 15, 2026 12:30 PM
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
GlobeNewswire · Jun 30, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Dec 2025
See GNLX's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.